secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001493152-25-020891
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Aspire Biopharma holders approve reverse split (1:5-1:40) and 19.99%+ note issuance
--------------------------------------------------------------------------------

- Reverse stock split proposal passed: 24,965,481 for, 5,988,513 against, 29,704 abstain.
- Notes proposal under Nasdaq Rule 5635(d) passed: 19,852,827 for, 3,747,867 against, 7,374,427 broker non-votes.
- Reverse split ratio range 1:5 to 1:40; board has discretion to implement within one year.
- Notes issued under Aug 19, 2025 purchase agreements; conversion floor price is 20% of 5-day avg closing prior to closing.
- Ticker ASBP (common) and ASBPW (warrants) listed on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315225020891/0001493152-25-020891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315225020891/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-020891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer